Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Carcinoma in Situ 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 252Biopsy 222Nivolumab 69Cyclophosphamide 65Carboplatin 56Radiation 53Paclitaxel 53X-Rays 52pembrolizumab 51Taxes 51Immunoglobulin G 51Disulfides 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 35Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 30venetoclax 27Cytarabine 27Rituximab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Histamine Antagonists × 1 year × Clear all
NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡